06/18/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 6/18/2020. Several countries affected by COVID-19 have seen increases in levels of violence occurring in the home, including violence against children, intimate partner violence, and violence against older people. Countries also face increasing challenges in maintaining support and care for survivors of violence. This seven-page brief compiles key actions that the health sector can undertake within a multi-sectoral response to prevent or mitigate interpersonal violence based on existing WHO guidance. (PDF)
06/17/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 6/17/2020. This five-page scientific brief provides the rationale for the changes made to the clinical management of COVID-19 guidance and recommendations on the criteria for discharging patients from isolation, based on recent scientific evidence. WHO will update these criteria as more information becomes available. (PDF)
06/16/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/16/2020. This three-page letter, issued on June 16, 2020, is notification of the revocation of the Emergency Use Authorization for the DPP® COVID-19 IgM/IgG System, which received an Emergency Use Authorization from the Food and Drug Administration on April 14, 2020. (PDF)
06/16/2020 12:00 AM EDT
Source: United Nations Office for Disaster Risk Reduction (UNDRR). Published: 6/16/2020. This 23-page paper focuses on actions taken by disaster risk reduction (DRR) actors in Africa in relation to COVID-19. It describes the integration of biological hazards in DRR strategies, by looking at eight DRR strategies from countries in Sub-Saharan Africa. It also looks at roles and responsibilities of DRR agencies in the response to COVID-19 and, by looking at contingency plans available online, describes common characteristics of response planning for COVID-19. (PDF)
06/15/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/15/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the BioCode SARS-CoV-2 Assay. The BioCode SARS-CoV-2 Assay is authorized for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
06/15/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/15/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the SARS-CoV-2 RBD IgG test. The SARS-CoV-2 RBD IgG test is authorized for the detection of IgG antibodies to SARS-CoV-2 in human serum. (PDF)
06/15/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/15/2020. This web page answers questions about adverse event reporting for medical devices distributed under Emergency Use Authorizations (EUAs) or that are the subject of COVID-19-related guidance documents, and points out a number of adverse event reporting-related resources. (Text)
06/15/2020 12:00 AM EDT
Source: Henry J. Kaiser Family Foundation. Published: 6/15/2020. This brief explores the extent to which state and federal data on coronavirus in long-term care (LTC) facilities differ and discusses the likely causes for these differences. While federal reporting offers promise for analyzing the intersection of COVID-19 and LTC facilities, state data will continue to play a role in highlighting the scope of the crisis across facility types and trends in COVID-19 within these facilities over time. (Text)
06/15/2020 12:00 AM EDT
Source: University of Illinois at Chicago, School of Public Health. Published: 6/15/2020. This tool was developed to measure experiences during the COVID-19 pandemic among South African adolescent girls (ages 15-19 years) and their mothers/caregivers within the IMARA (Informed, Motivated, Aware and Responsible Adolescents and Adults) study. It addresses psychological experiences (e.g., stress) and coping strategies, as well as effects of COVID-19 on mother-daughter relationships, living situations, sexual risk behaviors (e.g., frequency of sexual intercourse, drug/alcohol use), and health practices (e.g., adherence to medication). It is designed to be completed via self-report, either in person or over the telephone. Questions Adapted From: -Q1 is from the COVID-19 Exposure and Family Impact Survey (CEFIS), developed by The Center for Pediatric Traumatic Stress -Qs 2-12 are adapted from the COVID-19 Questionnaire Child Self-Report Primary Version, Environmental Influences on Child Health Population: Adults and Teens Length: 23 questions Time to Complete: 7-8 minutes Mode of Administration: Online (e.g., computer-assisted interview) Telephone Administered by: Trained Lay Examiner/Interviewer Language(s): English; Xhosa (PDF)
06/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/13/2020. This three-page fact sheet informs healthcare providers (HCP) of the significant known and potential risks and benefits of the emergency use of the Negative-pressure Respiratory System with Advanced Ventilation Return (NRSAVR-100). This device is authorized for use by HCP as an extra layer of barrier protection in addition to personal protective equipment (PPE) to prevent HCP exposure to pathogenic biological airborne particulates by providing isolation of hospitalized patients with suspected or confirmed diagnosis of COVID-19, at the time of definitive airway management, when performing medical procedures, or during transport of such patients during the COVID-19 pandemic. (PDF)
06/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/13/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of decontaminated, compatible N95 respirators. These compatible N95 respirators are NIOSH-approved non-cellulose N95 respirators without exhalation valves that have been decontaminated using the Technical Safety Service’s 20-CS Decontamination System. (PDF)
06/13/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 6/13/2020. This web page is intended to provide guidance on the appropriate use of COVID-19 testing among nursing home residents and healthcare personnel and does not dictate the determination of payment decisions or insurance coverage of such testing, except as may be otherwise referenced (or prescribed) by another entity or federal or state agency. It provides reorganized recommendations to address viral testing of healthcare personnel (HCP), viral testing of residents, and viral testing in response to an outbreak. (Text)
06/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/13/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the KPMAS COVID-19 Test. The KPMAS COVID-19 Test is authorized for use on nasal swab specimens self-collected by individuals at home, using the KPMAS COVID-19 Home Collection Kit, when determined by a healthcare provider to be appropriate. (PDF)
06/12/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/12/2020. This one-page letter authorizes the emergency use of the Corneum SARS-CoV-2 Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
06/12/2020 12:00 AM EDT
Source: Center for Health Security [Johns Hopkins University, Bloomberg School of Public Health]. Published: 6/12/2020. This 96-page document is designed to be a practical planning tool to help higher education institutions in two ways. First, the guide poses four central questions to determine if your institution is prepared to reopen for each of the major COVID-19 phases. Second, the guide is organized into leadership, cross-functional, and functional workgroups to support comprehensive planning efforts across various institutional groups. (PDF)
06/11/2020 12:00 AM EDT
Source: U.S. House of Representatives, Committee on Appropriations. Published: 6/11/2020. This two-hour Congressional hearing is an oversight hearing on the Indian Health Service’s response to the coronavirus outbreak in Indian Country. Witnesses detail how Tribal communities are disproportionately feeling the effects of the COVID-19 pandemic. (Video or Multimedia)
06/09/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/9/2020. This one-page letter authorizes the emergency use of the Warrior Diagnostics SARS-CoV-2 Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
06/04/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/4/2020. This one-page letter authorizes the emergency use of the NEcov19 RT-PCR Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
06/02/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/2/2020. This one-page letter authorizes the emergency use of the CSI SARS-CoV-2 RT PCR test, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
06/01/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/1/2020. This one-page letter authorizes the emergency use of the Aspirus SARS-CoV-2 rRT-PCR Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
06/01/2020 12:00 AM EDT
Source: University of North Carolina at Chapel Hill (UNC). Published: 6/2020. The COVID-19 and Telemental Health Service Use Survey was developed to help researchers and clinicians better understand how COVID-19 has affected the mental health of respondents, and their telemental health service use. Telemental health services include the use of voice call, video call, text messaging, mobile app, web-based formats (e.g., website, email), internet support group, or chat room to receive mental health treatment or counseling. The Institutional Review Board of the University of North Carolina at Chapel Hill provided the study a notification of exemption from further review (IRB Study #20-1588). Population: Adults Only Length: 26 items Time to Complete: 8 minutes Mode of Administration: Online (e.g., computer-assisted interview) Administered by: Self Administered Language(s): English (PDF)
05/22/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/22/2020. This one-page letter authorizes the emergency use of the Exact Sciences SARS-CoV-2 (N gene detection) test, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
05/22/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/22/2020. This one-page letter authorizes the emergency use of the Express Gene 2019-nCoV RT-PCR Diagnostic Panel, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
05/22/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/22/2020. This one-page letter authorizes the emergency use of the Avera Institute for Human Genetics SARS-CoV-2 Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
05/20/2020 12:00 AM EDT
Source: Urban Indian Health Institute (UIHI). Published: 5/20/2020. This two-page fact sheet for clinicians provides information about COVID-19 antibody tests, and recommendations for using them. (PDF)
05/18/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/18/2020. This one-page letter authorizes the emergency use of the Color SARS-CoV-2 LAMP Diagnostic Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
05/18/2020 12:00 AM EDT
Source: Michigan State University (MSU). Published: 5/18/2020. In order to increase physical activity and reduce chronic stress on a population level, researchers and city planners are exploring features of the built environment, including access to urban green space that may promote healthy lifestyles. Parks serve as places to engage in physical activity (PA) in direct contact with nature -- called "green exercise" -- which has been shown to lower perceived stress and risk of chronic disease. In addition, research indicates that passive exposure to green space (e.g., visual, as in the sight of plants and trees, and auditory, as in birdsong) may lower stress. However, many adults may experience barriers to getting outdoors, visiting parks, and engaging in PA during COVID-19 lockdowns, particularly people with compromised immune systems like those living with cancer. Exploring both how and why physical activity and outdoor behaviors have changed can help us to further understand the decision-making process and potential interventions that will benefit the health and well-being of breast cancer patients. Questions Adapted From: Questions about usage of outdoor spaces were both novel and adapted from University of Minnesota and Kansas State University surveys on outdoor activities during COVID-19. Perceived stress scale from Cohen (Cohen, S., T. Kamarck, and R. Mermelstein, A global measure of perceived stress. Journal of Health and Social Behavior, 1983. 24: p. 385-396). Quality of life questions from PROMIS (Hays, R.D., et al., Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation, 2009. 18(7): p. 873-880). Symptom experience from Cleeland (Cleeland, C.S., Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr, 2007(37): p. 16-21). Population: Adults Only Length: 150 questions, including health and demographic questions Time to Complete: 20 minutes Mode of Administration: Online (e.g., computer-assisted interview) Administered by: Self Administered Language(s): English (PDF)
05/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/13/2020. This one-page letter authorizes the emergency use of the One Health Laboratories SARS-CoV-2 Real-Time RT-PCR Test, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
05/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/13/2020. This one-page letter authorizes the emergency use of the Cedars-Sinai SARS-CoV-2 Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
05/08/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 5/8/2020. This nine-page details the Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, Fresenius Propoven 2% (propofol 20 mg/mL) Emulsion 100 mL, to maintain sedation via continuous infusion in patients greater than 16 years old who require mechanical ventilation in an intensive care unit (ICU) setting during the 2019 coronavirus disease (COVID-19) pandemic. (PDF)
05/01/2020 12:00 AM EDT
Source: Federal Emergency Management Agency [Department of Homeland Security] (FEMA). Published: 5/2020. This 41-page training program sets forth a structure for national training and establishes the roles and responsibilities of FEMA and members of the National Incident Management System (NIMS) stakeholder community. It identifies specific activities for developing, maintaining, and sustaining a training program that prepares all incident personnel to understand their respective responsibilities and work together during incidents. (PDF)
05/01/2020 12:00 AM EDT
Source: National Institute on Drug Abuse (NIDA). Published: 5/1/2020. C3PNO fosters collaborations and data sharing across the National Institute on Drug Abuse (NIDA) cohorts. C3PNO manages and stimulates the use of the NIDA longitudinal cohorts and addresses high priority research on HIV/AIDS in the context of substance misuse. In response to the COVID-19 pandemic, we have crafted a cross-cutting survey of COVID-19 related risk behaviors and effects. Questions Adapted From: Various sources and original questions Population: Adults and Teens High Risk/Special/Unique Populations Multiple Groups Other Sexual or Gender Minorities Substance users, those at risk for or living with HIV/AIDS, men who have sex with men Length: Up to 65 questions but much shorter for non-active substance users Time to Complete: 15 minutes Mode of Administration: Online (e.g., computer-assisted interview) Telephone Administered by: Self Administered Trained Lay Examiner/Interviewer Special Considerations: May be conducted by interviewer but designed primarily for online survey Language(s): English (PDF)
04/01/2020 12:00 AM EDT
Source: American College of Emergency Physicians (ACEP). Published: 4/2020. This web page provides information about a new poll that reveals public concerns around seeking medical care during the current outbreak of the COVID-19 pandemic and support for federal efforts to protect those on the frontline. The data also confirm a worrisome trend across emergency departments of people who are avoiding getting the medical care they need. (Text)
No hay comentarios:
Publicar un comentario